Financial Performance - Revenue for the six months ended June 30, 2021, was HKD 737,374,000, representing a 128% increase from HKD 323,835,000 in the same period of 2020[12] - Gross profit for the same period was HKD 622,694,000, up 144% from HKD 254,710,000 year-on-year[12] - Profit before tax increased to HKD 183,074,000, a 216% rise compared to HKD 57,790,000 in the prior year[12] - Net profit for the period was HKD 162,186,000, compared to HKD 49,188,000 in the previous year, marking a 229% increase[12] - The total comprehensive income for the period was HKD 180,212,000, significantly higher than HKD 2,826,000 in the same period of 2020[12] - The profit for the six months ended June 30, 2021, was HKD 218,712,000, compared to HKD 69,667,000 for the same period in 2020, reflecting a growth of 213.5%[29] - The group’s profit for the period was approximately HKD 162.2 million, a 229.7% increase from approximately HKD 49.2 million in the same period last year[118] Assets and Liabilities - Total assets as of June 30, 2021, amounted to HKD 2,618,277,000, up from HKD 2,421,339,000 at the end of 2020[14] - The company's total liabilities increased to HKD 1,040,924,000 from HKD 995,148,000, reflecting a growth of 4.6%[14] - The net asset value of the company reached HKD 1,577,353,000, compared to HKD 1,426,191,000 at the end of 2020, indicating a 10.6% increase[14] - Cash and cash equivalents increased to HKD 657,754,000 as of June 30, 2021, compared to HKD 390,388,000 at the end of 2020, marking a growth of 68.6%[29] - The company’s total liabilities included convertible loans with a fair value determined to be insignificant as of June 30, 2021[79] Earnings and Dividends - Basic earnings per share for the period were HKD 0.2812, up from HKD 0.0851 in the same period last year[12] - The company declared an interim dividend of HKD 0.04 per ordinary share for the six months ended June 30, 2021, compared to no dividend in the same period of 2020[45] - The basic and diluted earnings per share for the six months ended June 30, 2021, were HKD 0.2812 and HKD 0.2738, respectively, based on a profit attributable to shareholders of approximately HKD 162.2 million[129] Cash Flow and Financing - Cash generated from operating activities increased significantly to HKD 209,824,000 in the first half of 2021, up from HKD 57,828,000 in the same period of 2020, reflecting improved operational efficiency[18] - The net cash used in financing activities was HKD (37,688,000) for the six months ended June 30, 2021, an improvement from HKD (43,955,000) in the same period of 2020[29] - The total financing cost for the period was approximately HKD 5.4 million, compared to HKD 3.4 million in the same period last year[121] Research and Development - The group has initiated a five-year R&D plan from 2021 to 2025 to enhance its R&D capabilities in the ophthalmology field[108] - The group is conducting multiple research and development projects at various clinical stages, including single-dose ophthalmic products and biologics[97] - Total R&D expenses amounted to approximately HKD 85.9 million, representing 11.7% of revenue, compared to 14.7% in the same period last year, with HKD 74.8 million capitalized[120] Market and Product Development - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by ongoing investments in new technologies and product development[19] - The estimated number of moderate to severe dry eye patients in China exceeded 117 million in 2019, indicating a significant market potential for the SkQ1 product[102] - The group has launched T-Bactum®, an antimicrobial oral care product, leveraging patented nano-emulsion technology[97] Employee and Management - The salary and other benefits paid to key management personnel amounted to HKD 4,827,000 for the six months ended June 30, 2021, compared to HKD 2,934,000 for the same period in 2020[93] - The group employed 1,308 full-time employees as of June 30, 2021, an increase from 1,242 full-time employees as of December 31, 2020[144] Corporate Governance - The audit committee reviewed the accounting principles and practices adopted by the group and discussed internal controls and financial reporting matters for the six months ended June 30, 2021[187] - The company has complied with the corporate governance code as per the listing rules throughout the review period[186] - All directors confirmed compliance with the standards set forth in the code regarding securities transactions during the six months ended June 30, 2021[191]
亿胜生物科技(01061) - 2021 - 中期财报